よむ、つかう、まなぶ。
参考資料15 COVID-19 vaccine safety update; Primary series in young children and booster doses in older children and adults, ACIP September 1, 2022 (36 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000208910_00052.html |
| 出典情報 | 第85回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、令和４年度第14回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会（合同開催）（10／7）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
VSD incidence rates of verified myocarditis/pericarditis in the 0–7 days after
Moderna vaccination in people ages 5–39 years, dose 2 and 1st booster*
1st booster dose
Moderna
Dose 2 primary series
Moderna
5-11 years**
Males
Females
12–15 years**
Males
Females
Incidence rate/
million doses (95% CI)
Cases
1st boosters
admin
Incidence rate/
million doses (95% CI)
Cases
Dose 2
admin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
16–17 years**
Males
Females
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
18–29 years
Males
Females
19
0
195,809
243,560
97.0 (58.4 – 151.5)
0.0 (0.0 – 12.3)
7
1
109,337
156,707
64.0 (25.7 – 131.9)
6.4 (0.2 – 35.6)
30–39 years
Males
Females
8
1
216,583
259,780
36.9 (15.9 – 72.8)
3.9 (0.1 – 21.4)
1
2
149,468
191,765
6.7 (0.2 – 37.3)
10.4 (1.3 – 37.7)
*Primary series surveillance for people ages ≥18 years ended May 21, 2022, all other data through August 20, 2022.
**Monitoring ongoing, no data provided if less than 2,500 doses given in a subgroup.
36
Moderna vaccination in people ages 5–39 years, dose 2 and 1st booster*
1st booster dose
Moderna
Dose 2 primary series
Moderna
5-11 years**
Males
Females
12–15 years**
Males
Females
Incidence rate/
million doses (95% CI)
Cases
1st boosters
admin
Incidence rate/
million doses (95% CI)
Cases
Dose 2
admin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
16–17 years**
Males
Females
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
18–29 years
Males
Females
19
0
195,809
243,560
97.0 (58.4 – 151.5)
0.0 (0.0 – 12.3)
7
1
109,337
156,707
64.0 (25.7 – 131.9)
6.4 (0.2 – 35.6)
30–39 years
Males
Females
8
1
216,583
259,780
36.9 (15.9 – 72.8)
3.9 (0.1 – 21.4)
1
2
149,468
191,765
6.7 (0.2 – 37.3)
10.4 (1.3 – 37.7)
*Primary series surveillance for people ages ≥18 years ended May 21, 2022, all other data through August 20, 2022.
**Monitoring ongoing, no data provided if less than 2,500 doses given in a subgroup.
36